Bioventus Inc (NASDAQ:BVS) — Market Cap & Net Worth
Market Cap & Net Worth: Bioventus Inc (BVS)
Bioventus Inc (NASDAQ:BVS) has a market capitalization of $576.00 Million ($576.00 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11814 globally and #2814 in its home market, demonstrating a 4.12% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioventus Inc's stock price $10.11 by its total outstanding shares 66976477 (66.98 Million). Analyse BVS cash flow conversion to see how efficiently the company converts income to cash.
Bioventus Inc Market Cap History: 2021 to 2026
Bioventus Inc's market capitalization history from 2021 to 2026. Data shows change from $970.49 Million to $677.13 Million (-11.57% CAGR).
Index Memberships
Bioventus Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.02% | #305 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #1134 of 3165 |
Weight: Bioventus Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Bioventus Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioventus Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.88x
Bioventus Inc's market cap is 0.88 times its annual revenue
Latest Price to Earnings (P/E) Ratio
21.92x
Bioventus Inc's market cap is 21.92 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $970.49 Million | $430.90 Million | $19.38 Million | 2.25x | 50.09x |
| 2022 | $174.81 Million | $512.12 Million | -$158.70 Million | 0.34x | N/A |
| 2023 | $352.97 Million | $512.35 Million | -$156.23 Million | 0.69x | N/A |
| 2024 | $703.25 Million | $573.28 Million | -$33.54 Million | 1.23x | N/A |
| 2025 | $498.30 Million | $568.09 Million | $22.73 Million | 0.88x | 21.92x |
Competitor Companies of BVS by Market Capitalization
Companies near Bioventus Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Bioventus Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #141 globally with a market cap of $155.56 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #208 globally with a market cap of $112.79 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #230 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #236 globally with a market cap of $102.56 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #141 | Abbott Laboratories | NYSE:ABT | $155.56 Billion | $89.46 |
| #208 | Stryker Corporation | NYSE:SYK | $112.79 Billion | $294.73 |
| #230 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #236 | Medtronic PLC | NYSE:MDT | $102.56 Billion | $80.00 |
Bioventus Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Bioventus Inc's market cap moved from $970.49 Million to $ 677.13 Million, with a yearly change of -11.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $677.13 Million | +35.89% |
| 2025 | $498.30 Million | -29.14% |
| 2024 | $703.25 Million | +99.24% |
| 2023 | $352.97 Million | +101.92% |
| 2022 | $174.81 Million | -81.99% |
| 2021 | $970.49 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Bioventus Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $576.00 Million USD |
| MoneyControl | $576.00 Million USD |
| MarketWatch | $576.00 Million USD |
| marketcap.company | $576.00 Million USD |
| Reuters | $576.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioventus Inc
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis… Read more